FLSM
PRTA icon

Frazier Life Sciences Management’s Prothena Corp PRTA Stock Holding History

Frazier Life Sciences Management’s Portfolio PRTA Stock Details PRTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-127,900
Closed -$6.17M – 53
2023
Q3 		$6.17M Hold
127,900
– – 0.41% 40
2023
Q2 		$8.73M Hold
127,900
– – 0.52% 35
2023
Q1 		$6.2M Hold
127,900
– – 0.45% 39
2022
Q4 		$7.71M Buy
+127,900
New +$7.49M 0.48% 34

Other funds holding PRTA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Life Sciences Management's PRTA Position: Q4 2023 in Review

Frazier Life Sciences Management sold out of Prothena Corp (PRTA) in Q4 2023, closing a stake of 127,900 shares — an estimated $6.17M sold.

Frazier Life Sciences Management first reported a position in PRTA in Q4 2022 and held it in 4 quarters. The position peaked at $8.73M in Q2 2023. 187 funds tracked by Wall St. Rank hold PRTA as of Q4 2023.

  • Frazier Life Sciences Management reported no remaining Prothena Corp position as of Q4 2023 after selling out during the quarter.
  • Frazier Life Sciences Management sold 127,900 Prothena Corp shares in Q4 2023, an estimated $6.17M.
  • Frazier Life Sciences Management first reported a position in Prothena Corp in Q4 2022 and held it in 4 quarters.
  • Frazier Life Sciences Management's Prothena Corp position peaked at $8.73M in Q2 2023.
  • 187 funds tracked by Wall St. Rank held Prothena Corp as of Q4 2023.

Based on Frazier Life Sciences Management's 13F filing for Q4 2023, filed 14 Feb 2024.